BDBM610680 5-[(2R,6S)-2-methyl-6-[[4-[(5R)-5-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl]piperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile and 5-[(2R,6S)-2-methyl-6-[[4-[(5S)-5-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl]piperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile::US11713327, Example 74

SMILES C[C@@H]1CN(C[C@H](CN2CCN(CC2)c2cc3[C@@H](C)NCCc3cn2)O1)c1ccc(C#N)c2ncccc12

InChI Key InChIKey=ZGBNUNSLSXFCDN-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 610680   

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM610680(US11713327, Example 74 | 5-[(2R,6S)-2-methyl-6-[[4...)
Affinity DataIC50: 2.00E+4nMAssay Description:The hERG channel inhibition assay is a highly sensitive measurement that identifies compounds exhibiting hERG inhibition related to cardiotoxicity in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent